Damora Therapeutics (DMRA) Interest Coverage Ratio (2019 - 2026)
Damora Therapeutics (DMRA) posted Interest Coverage Ratio of 2.7 for Q1 2026, up 99.99% on a QoQ basis from 40339.2 in Q4 2025, and up 90.87% year-over-year from 1.41 in Q1 2025.
Damora Therapeutics (DMRA) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Damora Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 2.7 for Q1 2026.
- Quarterly Interest Coverage Ratio rose 90.87% year-over-year to 2.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.93 (up 90.36% YoY) and the FY2025 annual result came in at 2.8, down 744.29% from the prior year.
- Interest Coverage Ratio was 2.7 for Q1 2026 at Damora Therapeutics, up from 40339.2 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2.7 in Q1 2026 and bottomed at 40339.2 in Q4 2025.
- A 5-year average of 2443.67 and a median of 70.93 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 97.6% — and 2025, when it slumped 18643.93%.
- Damora Therapeutics' Interest Coverage Ratio stood at 87.26 in 2022, then surged by 55.29% to 39.01 in 2023, then tumbled by 451.66% to 215.21 in 2024, then slumped by 18643.93% to 40339.2 in 2025, then soared by 99.99% to 2.7 in 2026.
- Business Quant data shows DMRA's Interest Coverage Ratio at 2.7 in Q1 2026, 40339.2 in Q4 2025, and 157.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -2.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.70 |
| Dec 31, 2025 | -40,339.20 |
| Sep 30, 2025 | -157.80 |
| Jun 30, 2025 | -38.44 |
| Mar 31, 2025 | -29.53 |
| Dec 31, 2024 | -215.21 |
| Sep 30, 2024 | -76.80 |
| Jun 30, 2024 | -116.19 |
| Mar 31, 2024 | -62.40 |
| Dec 31, 2023 | -39.01 |
| Sep 30, 2023 | -70.93 |
| Jun 30, 2023 | -3.43 |
| Mar 31, 2023 | -9.43 |
| Dec 31, 2022 | -87.26 |
| Sep 30, 2022 | -101.66 |
| Jun 30, 2022 | -142.68 |
| Mar 31, 2022 | -49.78 |
| Dec 31, 2021 | -122.44 |
| Sep 30, 2021 | -6.28 |
| Jun 30, 2021 | -3.07 |